Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

All NewsOctober 17, 2025

Novartis’ five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent